Neurocrine
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.About NBIX
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.
NBIX Key Statistics
Stock Snapshot
With a market cap of 12.45B, Neurocrine(NBIX) trades at $124.00. The stock has a price-to-earnings ratio of 26.58.
On 2026-02-15, Neurocrine(NBIX) stock moved within a range of $123.36 to $126.50. With shares now at $124.00, the stock is trading +0.5% above its intraday low and -2.0% below the session's peak.
Trading activity shows a volume of 2.2M, compared to an average daily volume of 1.53M.
The stock's 52-week range extends from a low of $84.23 to a high of $160.18.
The stock's 52-week range extends from a low of $84.23 to a high of $160.18.
NBIX News
In the past week, Neurocrine Biosciences reported its fourth-quarter and full-year 2025 results, with revenue rising to US$805.5 million for the quarter and US$...
Neurocrine Biosciences (NasdaqGS:NBIX) is rolling out new products, including Chronesity and CRENESSITY, alongside a broad set of pipeline updates. The company...
Neurocrine Biosciences ((NBIX)) has held its Q4 earnings call. Read on for the main highlights of the call. Valentine's Day Sale - 70% Off Unlock hedge fund-lev...
Analyst ratings
86%
of 29 ratingsMore NBIX News
RBC Capital lowered the firm’s price target on Neurocrine (NBIX) to $177 from $180 and keeps an Outperform rating on the shares. The company reported a solid qu...
Tazeen Ahmad, an analyst from Bank of America Securities, reiterated the Buy rating on Neurocrine. The associated price target was lowered to $190.00. Valentine...
Citi analyst Yigal Nochomovitz raised the firm’s price target on Neurocrine (NBIX) to $204 from $203 and keeps a Buy rating on the shares. The firm updated the...
Analyst Ami Fadia from Needham maintained a Buy rating on Neurocrine and increased the price target to $185.00 from $184.00. Valentine's Day Sale - 70% Off Unlo...
If you are wondering whether Neurocrine Biosciences is fairly priced or offering value right now, you are not alone. This article is designed to help you frame...
AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX AD...
(RTTNews) - Neurocrine Biosciences Inc (NBIX) announced earnings for its fourth quarter that Increases, from last year The company's earnings came in at $153.7...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.